Skip to main content
NCBI home page
Cancer Immunology, Immunotherapy : CII logoLink to Cancer Immunology, Immunotherapy : CII
. 1982 Nov;14(1):32–35. doi: 10.1007/BF00199429

Modifying the biological response in acute myeloid leukemia

II. Effect of BCG and leukemic cells on lymphocyte response to mitogens, and on helper and suppressor activity

Anabel Arends-Merino 1, Richardo Giscombe 1, Claudio Ogier 1, Peter Reizenstein 1, Anne-Marie Sjörgen 1, Jerzy Wasserman 1
PMCID: PMC11039267  PMID: 6218871

Abstract

Lymphocyte response to mitogens and to lymphocyte suppressor and monocyte helper activity was studied in 18 patients with acute myeloid leukemia in complete remission, and in 17 healthy controls. Ten patients were maintained with chemotherapy alone (CT), and eight received chemoimmunotherapy with BCG + leukemic cells (CIT).

In late remission the mitogen responsiveness was increased in CT patients and decreased in CIT patients.

No significant difference in lymphocyte suppressor activity could be demonstrated between patients and controls, or between CT and CIT.

When autologous CIT monocytes were added to mitogen-stimulated lymphocytes they acted as helper cells. CT monocytes, in contrast, seemed to act as suppressor cells. Control monocytes also acted as helper cells, but to a significantly lesser degree than CIT monocytes.

Keywords: Leukemia, Cancer Research, Acute Myeloid Leukemia, Complete Remission, Leukemic Cell

Footnotes

Fellow, Hospital Universitario de Caracas, Division of Hematology, Universidad Central de Venezuela, Caracas, Venezuela

Central Microbiological Laboratory of Stockholm Country Council

‘Anna Villa Rusconi’ fellow, Department of Internal Medicine, University of Ferrara, Italy

References

  • 1.Arends-Merino A, Sjögren AM, Reizenstein P (1982) Modifying the biological response in acute myeloid leukemia. I. BCG allogeneic leukemic cells and spontaneous cytotoxicity. Cancer Immunol Immunother (in press) [PubMed]
  • 2.Berlinger NT, Lopez C, Good RA. Facilitation or attenuation of mixed leukocyte culture responsiveness by adherent cells. Nature. 1976;260:145. doi: 10.1038/260145a0. [DOI] [PubMed] [Google Scholar]
  • 3.Blomgren H, Wasserman J. Activation of monocytes in vitro to produce lymphocyte dysfunctions. Int J Radiat Oncol Biol Phys. 1979;5:221. doi: 10.1016/0360-3016(79)90723-5. [DOI] [PubMed] [Google Scholar]
  • 4.Böyum A. Isolation of mononuclear cells and granulocytes from human blood. Scand J Clin Lab Invest. 1968;21:99. [PubMed] [Google Scholar]
  • 5.Gonzalez RL, Dan PC, Spitter LE. Altered regulation of mitogen responsiveness by suppressor cells in multiple sclerosis. Clin Exp Immunol. 1979;36:78. [PMC free article] [PubMed] [Google Scholar]
  • 6.Goodwin JS, Messner RP, Bankhurst AD, Peake GJ, Saih JH, Williams RC., Jr Prostaglandin-producing suppressor cells in Hodgkin's disease. N Engl J Med. 1977;297:963. doi: 10.1056/NEJM197711032971802. [DOI] [PubMed] [Google Scholar]
  • 7.Jerrels TR, Dean JH, Richardson GL, McCoy JL, Herberman RE. Role of suppressor cells in depression of in vitro lymphoproliferative responses of lung and breast cancer patients. J Natl Cancer Inst. 1978;61:1001. [PubMed] [Google Scholar]
  • 8.Juhlin I, Blomgren H, Wasserman J. Evidence for the appearance of non-specific inhibitor cells in the blood after radiation therapy for breast carcinoma. Cancer Lett. 1977;3:311. [Google Scholar]
  • 9.Kallenberg C, De Gast G, The T. Suppression of DNA synthesis by con A-activated human lymphatic role of monocytes in con A-induced suppression. Clin Exp Immunol. 1980;41:583. [PMC free article] [PubMed] [Google Scholar]
  • 10.Markensson JA, Lockshin MD, Rosenfeld B, Joachim C, Wallis J, Julie N, Fuzesi L (1979) Monocytes from patients with scleroderma shown to exert suppressor role in cell-mediated immunity. Rheum News Int, Sept: 6
  • 11.Matsuo K. Macrophage activation by viable BCG in tumor-bearing mice and its relation with delayed hypersensitivity. Fukuoka Igaku Zasshi. 1979;8:465. [PubMed] [Google Scholar]
  • 12.Meqirian R, Saba T, Stephenson J. Bacillus Calmette-Gúerin-induced macrophage stimulation: Humoral aspects. J Reticuloendothelial Soc. 1976;20:5. [PubMed] [Google Scholar]
  • 13.Miale TD, Stenke LÅ, Penchansky M, Lehtinen T, Reizenstein P. The role of monocytes in phagocytosis and mixed leukocyte reactivity in human acute myeloid leukemia. Immunol Commun. 1979;8:279. doi: 10.3109/08820137909050043. [DOI] [PubMed] [Google Scholar]
  • 14.Norris DA, Weston WL, Tubergen DG, Rose B, Odom LF. Improvement of monocyte chemotaxia with BCG immunotherapy in acute lymphoblastic leukemia: Comparation of chemotherapy versus chemotherapy plus immunotherapy as therapeutic regimens. Cancer Immunol Immunother. 1979;7:15–18. [Google Scholar]
  • 15.Pauly C, Vànky F, Hast R, Lindemalm C, Udén AM, Reizenstein P. Cell-mediated immunity in human acute myeloblastic leukemia. Cancer Immunol Immunother. 1978;5:1. [Google Scholar]
  • 16.Reizenstein P, Brenning G, Engstedt L, Franzén S, Gahrton G, Gullbring B, Holm G, Höcker P, Höglund S, Hörnsten P, Jameson S, Killander A, Killander D, Klein E, Lantz B, Lindemalm Ch, Lockner D, Lönnqvist B, Mellstedt H, Palmblad J, Pauli C, Skårberg KO, Udén AM, Vànky F, Wadman B. Effect of immunotherapy on survival and remission, duration in acute non lymphatic leukemia. In: Terry W, editor. Immunotherapy of cancer: Present status of trials in man. New York: Raven Press; 1978. p. 329. [Google Scholar]
  • 17.Reizenstein P, Ogier C, Sjögren AM. Immunotherapy versus chemotherapy of acute myeloid leukemia: Response to PHA, allogeneic lymphocyte and leukemic myeloblast of remission lymphocytes from leukemia patients. Recent Results Cancer Res. 1980;75:29. doi: 10.1007/978-3-642-81491-4_5. [DOI] [PubMed] [Google Scholar]
  • 18.Reizenstein P, Andersson B, Beran M (1980) Possible mechanism of action of immunotherapy of acute non-lymphatic leukemia. Macrophage production of colony-stimulating activity. Recent Results Cancer Res [DOI] [PubMed]
  • 19.Reizenstein P, Andersson B, Björkholm M, Brenning G, Engstedt L, Gahrton G, Hast R, Holm G, Hörnsten P, Killander A, Lantz B, Lindemalm Ch, Lockner D, Lönnqvist B, Mellstedt H, Palmblad J, Paul C, Simonsson B, Sjögren AM, Starfeldt AM, Udén AM, Wadman B, Öberg G, Ösby E. BCG plus leukemic cell therapy of patients with acute myelogeneous leukemia. Effect in groups with high and low remission rates. In: Terry W, editor. Immunotherapy of cancer. New York: Raven Press; 1982. [Google Scholar]
  • 20.Twomey JJ, Laughter A, Farrow S, Douglass CG. Hodgkin's disease. An immunodepleting and immunosuppressive disorder. Scand J Clin Lab Invest. 1975;56:467. doi: 10.1172/JCI108113. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Udén AM, Lindemalm C, Pauli C, Vànky F, Reizenstein P. Effects of immunotherapy and chemotherapy on immunocompetence. A study of patients with acute myeloblastic leukemia in remission. Cancer Immunol Immunother. 1978;4:239. [Google Scholar]
  • 22.Unsgaard G, Hammerström J, Lamvi K. Cytostatic effect on tumor cells induced in human monocytes by mediators from BCG-stimulated lymphocytes in MLC. Acta Pathol Microbiol Scand. 1979;3:169. [PubMed] [Google Scholar]
  • 23.Wood N, Bashir H, Greally J, Amos DB, Yunis EJ. A simple method of freezing and storing live lymphocytes. Tissue Antigens. 1977;2:27. doi: 10.1111/j.1399-0039.1972.tb00114.x. [DOI] [PubMed] [Google Scholar]
  • 24.Yu A, Walts H, Jaffe N, Parman R. Concomitant presence of tumor-specific cytotoxic and inhibitor lymphocytes in patients with osteogenic sarcoma. N Engl J Med. 1977;197:121. doi: 10.1056/NEJM197707212970301. [DOI] [PubMed] [Google Scholar]

Articles from Cancer Immunology, Immunotherapy : CII are provided here courtesy of Springer

RESOURCES